313 related articles for article (PubMed ID: 28207542)
1. Rifampicin-induced disseminated intravascular coagulation in pulmonary tuberculosis treatment: A case report and literature review.
Chen G; He JQ
Medicine (Baltimore); 2017 Feb; 96(7):e6135. PubMed ID: 28207542
[TBL] [Abstract][Full Text] [Related]
2. API TB Consensus Guidelines 2006: Management of pulmonary tuberculosis, extra-pulmonary tuberculosis and tuberculosis in special situations.
API Consensus Expert Committee
J Assoc Physicians India; 2006 Mar; 54():219-34. PubMed ID: 16800350
[TBL] [Abstract][Full Text] [Related]
3. [Agranulocytosis due to anti-tuberculosis drugs including isoniazid (INH) and rifampicin (RFP)--a report of four cases and review of the literature].
Shishido Y; Nagayama N; Masuda K; Baba M; Tamura A; Nagai H; Akagawa S; Kawabe Y; Machida K; Kurashima A; Komatsu H; Yotsumoto H
Kekkaku; 2003 Nov; 78(11):683-9. PubMed ID: 14672045
[TBL] [Abstract][Full Text] [Related]
4. A case of thrombocytopenia caused by rifampicin and pyrazinamide.
Bansal R; Sharma PK; Sharma A
Indian J Pharmacol; 2013; 45(4):405-7. PubMed ID: 24014922
[TBL] [Abstract][Full Text] [Related]
5. Rifampicin-induced acute kidney injury during the initial treatment for pulmonary tuberculosis: a case report and literature review.
Chiba S; Tsuchiya K; Sakashita H; Ito E; Inase N
Intern Med; 2013; 52(21):2457-60. PubMed ID: 24190152
[TBL] [Abstract][Full Text] [Related]
6. [Thrombocytopenia induced by rifampicin not previously sensitized: a case presentation].
Neino Mourtala Mohamed A; Tummino C; Gouitaa M; Chanez P
Rev Mal Respir; 2013 Nov; 30(9):785-8. PubMed ID: 24267770
[TBL] [Abstract][Full Text] [Related]
7. Acute renal failure and disseminated intravascular coagulation associated with rifampin in tuberculosis treatment.
Costiniuk CT; McCarthy AE; Talreja H; Zimmerman D; Liu TT; Owen E; Angel JB
Int J Tuberc Lung Dis; 2011 Mar; 15(3):421. PubMed ID: 21333117
[No Abstract] [Full Text] [Related]
8. Rifampicin-induced antineutrophil cytoplasmic antibody-positive vasculitis: a case report and review of the literature.
Ji G; Zeng X; Sandford AJ; He JQ
Int J Clin Pharmacol Ther; 2016 Oct; 54(10):804-7. PubMed ID: 27569735
[TBL] [Abstract][Full Text] [Related]
9. [Effectiveness and problems of PZA-containing 6-month regimen for the treatment of new pulmonary tuberculosis patients].
Wada M
Kekkaku; 2001 Jan; 76(1):33-43. PubMed ID: 11211781
[TBL] [Abstract][Full Text] [Related]
10. Isoniazid- and streptomycin-resistant miliary tuberculosis complicated by intracranial tuberculoma in a Japanese infant.
Ishiwada N; Tokunaga O; Nagasawa K; Ichimoto K; Kinoshita K; Hishiki H; Kohno Y
Tohoku J Exp Med; 2013 Mar; 229(3):221-5. PubMed ID: 23470647
[TBL] [Abstract][Full Text] [Related]
11. [Thrombocytopenia following a re-introduction of rifampicin in a daily treatment. Apropos of a case].
Beji M; Louzir B; Ben Rhomdane N; Zouari M; Mtimet B; Daghfous J
Tunis Med; 1995 May; 73(5):201-3. PubMed ID: 9507284
[No Abstract] [Full Text] [Related]
12. Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pulmonary tuberculosis.
Dawson R; Diacon AH; Everitt D; van Niekerk C; Donald PR; Burger DA; Schall R; Spigelman M; Conradie A; Eisenach K; Venter A; Ive P; Page-Shipp L; Variava E; Reither K; Ntinginya NE; Pym A; von Groote-Bidlingmaier F; Mendel CM
Lancet; 2015 May; 385(9979):1738-1747. PubMed ID: 25795076
[TBL] [Abstract][Full Text] [Related]
13. [Short-term therapy of lung tuberculosis using a fixed combination of isoniazid, rifampicin and pyrazinamide. Results after 2 years].
Brändli O; Haegi V; Villiger B; Bohn W; Baumann HR; Zäch R
Schweiz Med Wochenschr; 1989 Mar; 119(10):299-305. PubMed ID: 2652281
[TBL] [Abstract][Full Text] [Related]
14. Side-effects of drug regimens used in short-course chemotherapy for pulmonary tuberculosis. A controlled clinical study.
Zierski M; Bek E
Tubercle; 1980 Mar; 61(1):41-9. PubMed ID: 6989067
[TBL] [Abstract][Full Text] [Related]
15. Management of and risk factors related to hepatotoxicity during tuberculosis treatment.
Babalık A; Arda H; Bakırcı N; Ağca S; Oruç K; Kızıltaş S; Cetintaş G; Calışır HC
Tuberk Toraks; 2012; 60(2):136-44. PubMed ID: 22779934
[TBL] [Abstract][Full Text] [Related]
16. Disseminated intravascular coagulopathy associated with rifampicin.
Ip M; Cheng KP; Cheung WC
Tubercle; 1991 Dec; 72(4):291-3. PubMed ID: 1811361
[TBL] [Abstract][Full Text] [Related]
17. Hepatotoxicity of antitubercular treatments. Rationale for monitoring liver status.
Durand F; Jebrak G; Pessayre D; Fournier M; Bernuau J
Drug Saf; 1996 Dec; 15(6):394-405. PubMed ID: 8968694
[TBL] [Abstract][Full Text] [Related]
18. [Leukopenia due to anti-tuberculous chemotherapy including rifampicin and isoniazid].
Nagayama N; Shishido Y; Masuda K; Baba M; Tamura A; Nagai H; Akagawa S; Kawabe Y; Machida K; Kurashima A; Komatsu H; Yotsumoto H
Kekkaku; 2004 May; 79(5):341-8. PubMed ID: 15211874
[TBL] [Abstract][Full Text] [Related]
19. [Rifampicin in the treatment of active pulmonary tuberculosis. Controlled trial of isoniazid-rifampicin-thiocarlide versus isoniazid-streptomycin-thiocarlide in untreated tuberculosis. Treatment of relapses with the combination rifampicin-ethambutol-thiocarlide].
Chioléro R
Schweiz Med Wochenschr; 1974 Mar; 104(10):356-64. PubMed ID: 4206521
[No Abstract] [Full Text] [Related]
20. Recurrent disseminated intravascular coagulation caused by intermittent dosing of rifampin.
Havey TC; Cserti-Gazdewich C; Sholzberg M; Keystone JS; Gold WL
Am J Trop Med Hyg; 2012 Feb; 86(2):264-7. PubMed ID: 22302861
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
